CN109562156B - 犬特应性皮炎的治疗 - Google Patents

犬特应性皮炎的治疗 Download PDF

Info

Publication number
CN109562156B
CN109562156B CN201780025651.8A CN201780025651A CN109562156B CN 109562156 B CN109562156 B CN 109562156B CN 201780025651 A CN201780025651 A CN 201780025651A CN 109562156 B CN109562156 B CN 109562156B
Authority
CN
China
Prior art keywords
cmv
amino acid
acid sequence
seq
cil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780025651.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN109562156A (zh
Inventor
K·塔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saiba Animal Health AG
Original Assignee
Benchmark Animal Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Benchmark Animal Health Ltd filed Critical Benchmark Animal Health Ltd
Priority to CN202310179224.2A priority Critical patent/CN116688110A/zh
Publication of CN109562156A publication Critical patent/CN109562156A/zh
Application granted granted Critical
Publication of CN109562156B publication Critical patent/CN109562156B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/14011—Bromoviridae
    • C12N2770/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/14011—Bromoviridae
    • C12N2770/14023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780025651.8A 2016-04-27 2017-04-26 犬特应性皮炎的治疗 Active CN109562156B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310179224.2A CN116688110A (zh) 2016-04-27 2017-04-26 犬特应性皮炎的治疗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16167264.7 2016-04-27
EP16167264 2016-04-27
PCT/EP2017/059977 WO2017186813A1 (en) 2016-04-27 2017-04-26 Treatment of canine atopic dermatitis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310179224.2A Division CN116688110A (zh) 2016-04-27 2017-04-26 犬特应性皮炎的治疗

Publications (2)

Publication Number Publication Date
CN109562156A CN109562156A (zh) 2019-04-02
CN109562156B true CN109562156B (zh) 2023-03-10

Family

ID=56024099

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780025651.8A Active CN109562156B (zh) 2016-04-27 2017-04-26 犬特应性皮炎的治疗
CN202310179224.2A Pending CN116688110A (zh) 2016-04-27 2017-04-26 犬特应性皮炎的治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310179224.2A Pending CN116688110A (zh) 2016-04-27 2017-04-26 犬特应性皮炎的治疗

Country Status (17)

Country Link
US (1) US10946078B2 (https=)
EP (1) EP3448422A1 (https=)
JP (2) JP7039561B2 (https=)
KR (2) KR20220162800A (https=)
CN (2) CN109562156B (https=)
AR (1) AR108333A1 (https=)
AU (3) AU2017256727B2 (https=)
BR (1) BR112018071965A2 (https=)
CA (1) CA3019653A1 (https=)
CL (1) CL2018002960A1 (https=)
CO (1) CO2018011087A2 (https=)
EA (1) EA201892003A1 (https=)
MX (2) MX394254B (https=)
NZ (1) NZ747512A (https=)
UA (1) UA126852C2 (https=)
WO (1) WO2017186813A1 (https=)
ZA (1) ZA201806503B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40824A (fr) 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
MX2020006105A (es) * 2017-12-11 2020-11-09 Ubi Ip Holdings Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.
CA3093539A1 (en) 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
AU2019236328B2 (en) 2018-03-16 2025-10-09 Zoetis Services Llc Peptide vaccines against Interleukin-31
WO2020128037A1 (en) * 2018-12-20 2020-06-25 Saiba Gmbh Virus-like particles of cmv modified by fusion

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023103A (zh) * 2004-09-21 2007-08-22 赛托斯生物技术公司 包含ap205外壳蛋白和抗原性多肽的融合蛋白的病毒样颗粒
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN108064276A (zh) * 2014-10-22 2018-05-22 塞坝有限责任公司 Cmv的修饰病毒样颗粒

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040024004A1 (en) 2001-05-04 2004-02-05 Sherman Barry M. Novel compositions and methods for enhancing potency or reducing adverse side effects of opioid agonists
AU2002339224B2 (en) 2001-09-14 2008-10-09 Kuros Us Llc Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
CA2580208A1 (en) * 2004-09-21 2006-03-30 Cytos Biotechnology Ag Virus-like particles comprising a fusion protein of the coat protein of ap205 and an antigenic polypeptide
JP2008530132A (ja) * 2005-02-14 2008-08-07 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１ｒａアンタゴニストを用いて皮膚障害を治療する方法
EP1973608A1 (en) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
WO2008112674A1 (en) 2007-03-12 2008-09-18 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
US8465756B2 (en) * 2009-08-12 2013-06-18 National Health Research Institutes Immunogenic peptides of tumor associated antigen L6 and uses thereof in cancer therapy
WO2014107344A1 (en) 2013-01-04 2014-07-10 Bristol-Myers Squibb Company Positive allosteric modulators and silent allosteric modulators of the opioid receptor
WO2015042596A1 (en) 2013-09-23 2015-03-26 Kindred Biosciences, Inc Treatment of atopic dermatitis in non-human animals

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023103A (zh) * 2004-09-21 2007-08-22 赛托斯生物技术公司 包含ap205外壳蛋白和抗原性多肽的融合蛋白的病毒样颗粒
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
CN108064276A (zh) * 2014-10-22 2018-05-22 塞坝有限责任公司 Cmv的修饰病毒样颗粒

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A Cucumber Mosaic Virus Based Expression System for the Production of Porcine Circovirus Specific Vaccines;Ákos Gellért等;《PLOS ONE》;20121231;第7卷(第12期);摘要、第1页的引言，第8-9页的讨论 *
An enhanced heterologous virus-like particle for human papillomavirus type 16 tumour immunotherapy;Khairunadwa Jemon等;《Plos One》;20130714;第8卷(第6期);摘要、第2页的材料与方法、第3-4页的结果 *
GenBank：AAQ82699.1;GenBank：AAQ82699.1;《GenBank》;20030922;第1页 *
IL-31与特应性皮炎的相关性研究进展;郑静等;《北京医学》;20091231;第31卷(第5期);第296-298页 *

Also Published As

Publication number Publication date
AU2017256727A1 (en) 2018-11-15
JP2022078254A (ja) 2022-05-24
US10946078B2 (en) 2021-03-16
UA126852C2 (uk) 2023-02-15
AU2026202093A1 (en) 2026-04-09
JP7039561B2 (ja) 2022-03-22
CL2018002960A1 (es) 2019-01-25
BR112018071965A2 (pt) 2019-03-06
CN116688110A (zh) 2023-09-05
KR20220162800A (ko) 2022-12-08
MX2022009171A (es) 2022-08-17
EP3448422A1 (en) 2019-03-06
JP7273214B2 (ja) 2023-05-12
NZ787511A (en) 2025-10-31
EA201892003A1 (ru) 2019-05-31
AU2022291431B2 (en) 2025-12-18
ZA201806503B (en) 2019-07-31
CO2018011087A2 (es) 2019-02-08
MX394254B (es) 2025-03-24
AU2017256727B2 (en) 2022-09-29
KR20190003948A (ko) 2019-01-10
AR108333A1 (es) 2018-08-08
US20190209668A1 (en) 2019-07-11
CA3019653A1 (en) 2017-11-02
AU2022291431A1 (en) 2023-03-30
JP2019515957A (ja) 2019-06-13
CN109562156A (zh) 2019-04-02
NZ747512A (en) 2023-05-26
WO2017186813A1 (en) 2017-11-02
KR102469478B1 (ko) 2022-11-23

Similar Documents

Publication Publication Date Title
JP7455785B2 (ja) 虫刺され過敏症の治療
CN114685626B (zh) Cmv的修饰病毒样颗粒
AU2022291431B2 (en) Treatment of canine atopic dermatitis
CN110381990A (zh) 马的瘙痒症的治疗
US10898569B2 (en) Treatment of peanut allergy
US20250281587A1 (en) Veterinary compositions of modified virus-like particles of cmv and feline il-1 beta mutein antigens
US20220332770A1 (en) High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier
EA045381B1 (ru) Лечение атопического дерматита собак
HK40077650B (zh) Cmv的修饰病毒样颗粒
HK1252263B (en) Treatment of insect bite hypersensitivity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230803

Address after: Indiana, USA

Patentee after: Lilan USA

Address before: Sheffield

Patentee before: BENCHMARK ANIMAL HEALTH Ltd.

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20240904

Address after: Swiss hole

Patentee after: Saiba Animal Health Co.,Ltd.

Country or region after: Switzerland

Address before: indiana

Patentee before: Lilan USA

Country or region before: U.S.A.